ARRDC3 as a Diagnostic and Prognostic Biomarker for Epithelial Ovarian Cancer Based on Data Mining

References

• Zhang Y, Luo G, Li M, et al. Global patterns and trends in ovarian cancer incidence: age, period and birth cohort analysis. BMC Cancer. 2019;19(1):984. doi:10.1186/s12885-019-6139-6
   PubMed Web of Science ®Google Scholar
• Webb PM, Jordan SJ. Epidemiology of epithelial ovarian cancer. Best Pract Res Clin Rheumatol. 2017;41:3–14. doi:10.1016/j.bpobgyn.2016.08.006
   Web of Science ®Google Scholar
• Jessmon P, Boulanger T, Zhou W, et al. Epidemiology and treatment patterns of epithelial ovarian cancer. Expert Rev Anticancer Ther. 2017;17(5):427–437. doi:10.1080/14737140.2017.1299575
   PubMed Web of Science ®Google Scholar
• Coleman RL, Oza AM, Lorusso D, et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, Phase 3 trial. Lancet. 2017;390(10106):1949–1961. doi:10.1016/S0140-6736(17)32440-6
   PubMed Web of Science ®Google Scholar
• Moore K, Colombo N, Scambia G, et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2018;379(26):2495–2505. doi:10.1056/NEJMoa1810858
   PubMed Web of Science ®Google Scholar
• González-Martín A, Pothuri B, Vergote I, et al. Niraparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2019;381(25):2391–2402. doi:10.1056/NEJMoa1910962
   PubMed Web of Science ®Google Scholar
• Weidle UH, Birzele F, Kollmorgen G, et al. Mechanisms and targets involved in dissemination of ovarian cancer. Cancer Genomics Proteomics. 2016;13(6):407–423. doi:10.21873/cgp.20004
   PubMed Web of Science ®Google Scholar
• Oka S, Masutani H, Liu W, et al. Thioredoxin-binding protein-2-like inducible membrane protein is a novel vitamin D3 and peroxisome proliferator-activated receptor (PPAR)gamma ligand target protein that regulates PPARgamma signaling. Endocrinology. 2006;147(2):733–743. doi:10.1210/en.2005-0679
   PubMed Web of Science ®Google Scholar
• Han SO, Kommaddi RP, Shenoy SK. Distinct roles for β-arrestin2 and arrestin-domain-containing proteins in β2 adrenergic receptor trafficking. EMBO Rep. 2013;14(2):164–171. doi:10.1038/embor.2012.187
   PubMed Web of Science ®Google Scholar
• Patwari P, Emilsson V, Schadt EE, et al. The arrestin domain-containing 3 protein regulates body mass and energy expenditure. Cell Metab. 2011;14(5):671–683. doi:10.1016/j.cmet.2011.08.011
   PubMed Web of Science ®Google Scholar
• Nabhan JF, Pan H, Lu Q. Arrestin domain-containing protein 3 recruits the NEDD4 E3 ligase to mediate ubiquitination of the beta2-adrenergic receptor. EMBO Rep. 2010;11(8):605–611. doi:10.1038/embor.2010.80
   PubMed Web of Science ®Google Scholar
• Lei D, Deng N, Wang S, et al. Upregulated ARRDC3 limits trophoblast cell invasion and tube formation and is associated with preeclampsia. Placenta. 2020;89:10–19. doi:10.1016/j.placenta.2019.10.009
   PubMed Web of Science ®Google Scholar
• Ogawa M, Kanda T, Higuchi T, et al. Possible association of arrestin domain-containing protein 3 and progression of non-alcoholic fatty liver disease. Int J Med Sci. 2019;16(7):909–921. doi:10.7150/ijms.34245
   PubMed Web of Science ®Google Scholar
• Shen X, Sun X, Sun B, et al. ARRDC3 suppresses colorectal cancer progression through destabilizing the oncoprotein YAP. FEBS Lett. 2018;592(4):599–609. doi:10.1002/1873-3468.12986
   PubMed Web of Science ®Google Scholar
• Xiao J, Shi Q, Li W, et al. ARRDC1 and ARRDC3 act as tumor suppressors in renal cell carcinoma by facilitating YAP1 degradation. Am J Cancer Res. 2018;8(1):132–143.
   PubMed Web of Science ®Google Scholar
• Takeuchi F, Kukimoto I, Li Z, et al. Genome-wide association study of cervical cancer suggests a role for ARRDC3 gene in human papillomavirus infection. Hum Mol Genet. 2019;28(2):341–348. doi:10.1093/hmg/ddy390
   PubMed Web of Science ®Google Scholar
• Tang Z, Li C, Kang B, et al. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45(W1):W98–W102. doi:10.1093/nar/gkx247
   PubMed Web of Science ®Google Scholar
• Rhodes DR, Yu J, Shanker K, et al. ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia. 2004;6(1):1–6. doi:10.1016/S1476-5586(04)80047-2
   PubMed Web of Science ®Google Scholar
• Strausberg RL, Feingold EA, Grouse LH, et al. Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences. Proc Natl Acad Sci USA. 2002;99(26):16899–16903.
   PubMed Web of Science ®Google Scholar
• Nagy Á, Lánczky A, Menyhárt O, et al. Validation of miRNA prognostic power in hepatocellular carcinoma using expression data of independent datasets. Sci Rep. 2018;8(1):9227. doi:10.1038/s41598-018-27521-y
   PubMed Web of Science ®Google Scholar
• Gao J, Aksoy BA, Dogrusoz U, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6(269):pl1. doi:10.1126/scisignal.2004088
   PubMed Web of Science ®Google Scholar
• Li T, Fan J, Wang B, et al. TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells. Cancer Res. 2017;77(21):e108–e110. doi:10.1158/0008-5472.CAN-17-0307
   PubMed Web of Science ®Google Scholar
• Lopes CT, Franz M, Kazi F, et al. Cytoscape web: an interactive web-based network browser. Bioinformatics. 2010;26(18):2347–2348. doi:10.1093/bioinformatics/btq430
   PubMed Web of Science ®Google Scholar
• Dennis G Jr, Sherman BT, Hosack DA, et al. DAVID: database for annotation, visualization, and integrated discovery. Genome Biol. 2003;4(5):P3. doi:10.1186/gb-2003-4-5-p3
   PubMed Web of Science ®Google Scholar
• Hu Y, Vinayagam A, Nand A, et al. Molecular interaction search tool (MIST): an integrated resource for mining gene and protein interaction data. Nucleic Acids Res. 2018;46(D1):D567–d574. doi:10.1093/nar/gkx1116
   PubMed Web of Science ®Google Scholar
• Liu YG, Teng YS, Shan ZG, et al. Arrestin domain containing 3 promotes helicobacter pylori-associated gastritis by regulating protease-activated receptor 1. JCI Insight. 2020;5(15):e135849. doi:10.1172/jci.insight.135849
   PubMed Web of Science ®Google Scholar
• Draheim KM, Chen HB, Tao Q, et al. ARRDC3 suppresses breast cancer progression by negatively regulating integrin beta4. Oncogene. 2010;29(36):5032–5047. doi:10.1038/onc.2010.250
   PubMed Web of Science ®Google Scholar
• Zheng Y, Lin ZY, Xie JJ, et al. ARRDC3 inhibits the progression of human prostate cancer through ARRDC3-ITGβ4 pathway. Curr Mol Med. 2017;17(3):221–229.
   PubMed Web of Science ®Google Scholar
• Wang D, Yang PN, Chen J, et al. Promoter hypermethylation may be an important mechanism of the transcriptional inactivation of ARRDC3, GATA5, and ELP3 in invasive ductal breast carcinoma. Mol Cell Biochem. 2014;396(1–2):67–77. doi:10.1007/s11010-014-2143-y
   PubMed Web of Science ®Google Scholar
• Arakaki AKS, Pan WA, Lin H, et al. The α-arrestin ARRDC3 suppresses breast carcinoma invasion by regulating G protein-coupled receptor lysosomal sorting and signaling. J Biol Chem. 2018;293(9):3350–3362. doi:10.1074/jbc.RA117.001516
   PubMed Web of Science ®Google Scholar
• Yao J, Xu C, Fang Z, et al. Androgen receptor regulated microRNA miR-182-5p promotes prostate cancer progression by targeting the ARRDC3/ITGB4 pathway. Biochem Biophys Res Commun. 2016;474(1):213–219. doi:10.1016/j.bbrc.2016.04.107
   PubMed Web of Science ®Google Scholar
• El-Arabey AA, Abdalla M, Abd-Allah AR. SnapShot; TP53 status and macrophages infiltration in TCGA-analyzed tumors. Int Immunopharmacol. 2020;86:106758. doi:10.1016/j.intimp.2020.106758
   PubMed Web of Science ®Google Scholar
• Chava S, Gupta R. Identification of the mutational landscape of gynecological malignancies. J Cancer. 2020;11(16):4870–4883. doi:10.7150/jca.46174
   PubMed Web of Science ®Google Scholar